Beyond PARP inhibitors, combinations of DNA-damage inducing agents with ICB have shown encouraging preclinical/clinical results, as exemplified by the recent FDA approval of atezolizumab (anti-PD-L1) in combination with carboplatin and etoposide for extensive-stage small cell lung cancers (SCLCs). The gene discussed is PARP1; the disease is small cell lung carcinoma.